Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

SOC Telemed, Inc. TLMD NASDAQ

NASDAQ Global Select • Healthcare • Medical - Care Facilities • US • USD

SharesGrow Score
27/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

SOC Telemed, Inc. (TLMD) is a Medical - Care Facilities company in the Healthcare sector, currently trading at $3.00. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $94M, +25.2%/yr average growth. Net income is $51M (loss), growing at -87.6%/yr. Net profit margin is -53.8% (negative). Gross margin is 32.1% (-7.2 pp trend).

Balance sheet: total debt is $87M against $167M equity (Debt-to-Equity (D/E) ratio 0.52, moderate). Current ratio is 3.32 (strong liquidity). Debt-to-assets is 31.6%. Total assets: $274M.

Analyst outlook: 0 / 4 analysts rate TLMD as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 21/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

TLMD SharesGrow Score Overview

32/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TLMD

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
TLMD: +25.2%/yr revenue is, -87.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet TLMD: Debt-to-Equity (D/E) ratio 0.52 (moderate), Current ratio is 3.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
TLMD: Gross margin is 32.1% (-7.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 4 analysts rate TLMD as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
TLMD: Net profit margin is -53.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.99-3
Volume946.55K
Avg Volume (30D)1.38M
Beta (1Y)-1.45
Share Statistics
EPS (TTM)-1.23
Shares Outstanding$41.35M
IPO Date2020-01-28
Employees226
Financial Highlights & Ratios
Revenue (TTM)$94.44M
Gross Profit$30.35M
EBITDA$-34.32M
Net Income$-50.85M
Operating Income$-43.59M
Total Cash$38.86M
Total Debt$86.71M
Net Debt$47.85M
Total Assets$274.23M
Price / Earnings (P/E)-2.4
Analyst Forecast
Rating ConsensusHold
Analysts Covering4
Buy 0% Hold 100% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS78472F1012

Price Chart

Track all markets on TradingView
TLMD
SOC Telemed, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Medical - Care Facilities
2.99 52WK RANGE 3.00

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message